Table 2:
Clinical characteristics of hypertrophic cardiomyopathy patients
| N=30 | |
|---|---|
| Age at diagnosis (years) | 14.0 ± 2.9 |
| Alive | 29 (97%) |
| Genetic Testing | 28 (93%) |
| Positive for known genetic mutation | 16 (57%) |
| Implantable Cardioverter Defibrillator (ICD) placed | 6 (20%) |
| Patients with ICD shocks delivered | 3 (50%) |
| History of septal myectomy | 3 (10%) |
| Use of medications | 16 (53%) |
| Angiotensin converting enzyme inhibitor | 1 (3%) |
| Beta-blocker | 15 (50%) |
| Calcium channel blocker | 1 (3%) |
| Aspirin | 1 (3%) |
| Other | 2 (10%) |
| Risk Factors for Sudden Cardiac Death | |
| Maximal septal thickness > 30mm | 3 (10%) |
| Syncope | 6 (20%) |
| Family history of sudden cardiac death | 11 (37%) |
| History of ventricular tachycardia | 3 (10%)* |
| Inadequate blood pressure response to exercise | 8 (27%) |
| History of aborted sudden death | 2 (7%) |
*
All non-sustained ventricular tachycardia